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Abstract
Background: In many low-income countries, the retail sector plays an important role in the treatment of malaria
and is increasingly being considered as a channel for improving medicine availability. Retailers are the last link in a
distribution chain and their supply sources are likely to have an important influence on the availability, quality and
price of malaria treatment. This article presents the findings of a systematic literature review on the retail sector
distribution chain for malaria treatment in low and middle-income countries.
Methods: Publication databases were searched using key terms relevant to the distribution chain serving all types
of anti-malarial retailers. Organizations involved in malaria treatment and distribution chain related activities were
contacted to identify unpublished studies.
Results: A total of 32 references distributed across 12 developing countries were identified. The distribution chain
had a pyramid shape with numerous suppliers at the bottom and fewer at the top. The chain supplying rural and
less-formal outlets was made of more levels than that serving urban and more formal outlets. Wholesale markets
tended to be relatively concentrated, especially at the top of the chain where few importers accounted for most of
the anti-malarial volumes sold. Wholesale price mark-ups varied across chain levels, ranging from 27% to 99% at
the top of the chain, 8% at intermediate level (one study only) and 2% to 67% at the level supplying retailers
directly. Retail mark-ups tended to be higher, and varied across outlet types, ranging from 3% to 566% in
pharmacies, 29% to 669% in drug shops and 100% to 233% in general shops. Information on pricing determinants
was very limited.
Conclusions: Evidence on the distribution chain for retail sector malaria treatment was mainly descriptive and
lacked representative data on a national scale. These are important limitations in the advent of the Affordable
Medicine Facility for Malaria, which aims to increase consumer access to artemisinin-based combination therapy
(ACT), through a subsidy introduced at the top of the distribution chain. This review calls for rigorous distribution
chain analysis, notably on the factors that influence ACT availability and prices in order to contribute to efforts
towards improved access to effective malaria treatment.
Background
In many low- and middle-income countries, the retail
sector plays an important role in the provision of
malaria treatment [1-14]. For example, it was the first
source of care for around 45% of households seeking
malaria treatment across four communities in Enugu
State, Nigeria [15] and in three rural districts of
Tanzania nearly 40% of all anti-malarial volumes were
dispensed within the retail sector [16]. Retail providers
tend to operate closer to homes [15,17-19] and offer a
more reliable and wider range of drugs than public
health providers [2,11,14,18-20], sometimes at lower
costs [14,21-23].
The market for anti-malarial drugs includes artemisi-
nin-based combination therapy (ACT), which is the
most effective drug regimen and the official first-line
treatment in most developing countries, non-artemisinin
drugs, some of which were recommended before the
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ACT era (e.g. chloroquine, amodiaquine, sulphadoxine-
pyrimethamine and quinine), and artemisinin mono-
therapies. These three product types are available under
different formulations including tablets, suppositories,
suspensions, syrups and liquid injectables. Some are sold
under their proprietary names, and referred to as inno-
vator brands when they are products patented by their
originators, or branded generics in the case of generic
versions of innovator products marketed under a differ-
ent name. Others are sold as unbranded generics with-
out a proprietary name.
Within the retail market, these products are sold by a
wide range of providers whose characteristics vary sub-
stantially across settings. Providers can be pharmacies,
drug shops, grocery stores, market stalls or itinerant
hawkers. In East and West Africa, drug shops that spe-
cialize in handling drugs play a major role, such as in
Tanzania where they accounted for 88% of retail sector
anti-malarial sales volumes [16]. Mobile vendors are
common in West Africa, but are rarely found in East
and Southern Africa [24]. Outlets staffed by trained
pharmacists are rare in all countries [17,25], and con-
centrated in urban areas, whilst drug shops can be
found in both urban and more densely populated rural
areas. Finally, general shops that sell drugs alongside
household goods are often the only medicine retailers in
more remote rural villages.
Pharmacies are generally authorized to stock both pre-
scription-only drugs and over-the-counter (OTC) pro-
ducts, while other outlets can only sell OTC drugs,
although in practice some illegally stock prescription-
only medicines [24]. Whilst anti-malarial drug availabil-
ity is relatively high in the retail sector [19,25-30], the
range of anti-malarials is generally lower in outlets
which are more remote or have less qualified staff
[19,25,28,31]. ACT is rarely available outside facilities
and pharmacies because of their high price relative to
older, less effective alternatives. For example, in six dis-
tricts of Zambia, ACT accounted for only 7% of all anti-
malarials sold in the retail sector [33] and in Tanzania,
the old monotherapy sulphadoxine-pyrimethamine (SP)
was the most commonly retailed anti-malarial, followed
by artemisinin monotherapies [34]. The availability of
artemisinin monotherapies is highly variable, but a
major cause of concern as their use is likely to contri-
bute to the development of artemisinin resistance [35].
Other concerns around the quality of care provided in
the retail sector relate to retailers’ lack of qualifications,
poor knowledge of drugs and dosages [36-39], and
stocking of unregistered [28,31] and sometimes substan-
dard or counterfeit drugs [6,19,40-44]. Although care
provided by pharmacies is far from perfect [45,46], most
of these concerns are directed to non-pharmacy outlets.
Drug shop staff are rarely qualified pharmacists [47],
having at best a basic nursing background [24,26] or
sometimes just secondary education [47]. General retai-
lers have even fewer qualifications and some are illiter-
ate [18,20].
These drug retailers are the last link in a chain of sup-
pliers and their practices are likely to be heavily influ-
enced by what happens further up the distribution
chain. Retail availability, for instance, will be affected by
which products are available from suppliers, the market-
ing strategies used to promote certain drugs, and the
registration of drugs and regulation of providers further
up the chain. Retail prices will be influenced by whole-
sale prices, and the cost of obtaining and storing goods.
Retail quality will be determined by how products have
been handled and stored higher up the chain. In turn,
the behaviour of suppliers in the chain will be influ-
enced by the nature of competition and regulation that
they face.
Understanding the distribution chain for anti-malarials
is, therefore, crucial in designing interventions to
improve retail sector care. This is of particular impor-
tance in the light of the implementation of the Afford-
able Medicines Facility for Malaria (AMFm), which will
rely on existing distribution chains to deliver heavily
subsidized ACT to consumers. This article aims to sup-
port such initiatives by summarizing the current state of
knowledge on the retail sector distribution chain for
malaria treatment in low- and middle-income countries.
Methods
Scope of the review
The retail sector distribution chain refers to all levels of
the in-country distribution chain, in other words to the
chain of wholesalers serving the retail sector. The focus is
on suppliers who operate from the point where commod-
ities leave the factory gate or port of entry down to those
directly supplying retailers. For the purpose of the review,
a taxonomy of suppliers was developed (Figure 1). Suppli-
ers who sell directly to retailers are termed terminal sup-
pliers. These buy from upstream suppliers, referred to as
primary suppliers if they are the point of entry into the
distribution chain, or intermediate suppliers if they them-
selves obtain drugs from primary suppliers.
Literature search and review strategies
The search strategy aimed to identify published, grey
and unpublished studies on the retail sector distribution
chain for malaria treatment in low- and middle-income
countries. Published studies were identified by searching
web-based databases, using key terms pertaining to mar-
ket structure and price mark-ups (Table 1). Grey and
unpublished sources were identified by searching the
websites of organizations involved in research related to
the distribution chain for malaria treatment in low and
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middle income countries and contacting key informants
within these institutions (the William J. Clinton Founda-
tion, Medicines for Malaria Venture, Dalberg Global
Development Advisors, Health Action International
Europe, MIT-Zaragoza International Logistics Program).
Searches were finalized in February 2009.
Studies were included if they provided data specifically
on anti-malarials for products stocked, volume sold and
mark-ups. Studies that looked at the structure of the dis-
tribution chain, in terms of supply sources, supplier num-
bers and characteristics for both anti-malarials and
medicines in general were also included on the basis that
anti-malarials are expected to follow the same distribution
route as other drugs and represent an important share of
all drugs distributed in developing countries.
The review focuses on wholesalers but includes two
aspects of retailer behaviour relevant to the study of the
distribution chain: their sources of supply and the mark-
up they add at the retail level. Other aspects of the retail
market, such as its structure and operations have been
reviewed elsewhere [24]. Studies were excluded if they
compared retail prices to international reference prices
without any information on price components across
distribution chain levels.
Results
Thirty-two references exploring the distribution chain
for anti-malarials and pharmaceutical drugs in general
were identified. The evidence they provide focuses
mainly on supply sources, with more limited attention
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Figure 1 Taxonomy of suppliers operating within the distribution chain. Suppliers directly serving retailers are referred to as terminal
suppliers. They buy from upstream suppliers, referred to as primary suppliers if they are the point of entry into the distribution chain after a
drug has left the factory gate, or intermediate suppliers if they themselves obtain drugs from primary suppliers.
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to the number and characteristics of suppliers, and anti-
malarial sales volumes and mark-ups (Table 2). Methods
used included document reviews and structured or
unstructured interviews with retailers, wholesalers and
informants working at central government level.
Structure of the distribution chain
This section summarizes evidence on the shape of the
distribution chain and the number and types of suppli-
ers operating at each level. Overall, the chain had a pyr-
amid shape similar to that of other private distribution
channels, with fewer suppliers at the top and more
numerous suppliers at the bottom [25,26,29,31,32,
48-55]. The number of levels within the chain ranged
from zero (in the case where retailers obtained drugs
directly from the factory gate) up to four levels (in the
case of a chain made up of terminal, two intermediate
and primary levels). The chain serving more remote out-
lets and those with less qualified staff tended to have
more numerous levels. There were two intermediate
levels of general wholesalers in the chain serving general
shops operating in three rural districts in Tanzania but
no intermediate level in the chain serving drug shops
located in the same districts [32]. In a rural district of
Uganda, two intermediate levels of wholesalers supplied
the chain down to general stores and market stalls
whilst the chain serving drug shops had a single inter-
mediate level of wholesalers [26].
Data on the total number of suppliers operating at
each level of the anti-malarial distribution chain were
generally lacking. When available, data mainly con-
cerned registered suppliers of pharmaceutical products
in general [25,26,31,48-50,52] and rarely provided infor-
mation on the total number of suppliers handling anti-
malarials [29,32,51,53]. Overall the number of importers
operating in a country was reported to range from 1 to
50 [53]. In Burkina Faso, there were 4 private importers
and in Uganda 15 importers and 50 wholesalers, with
the latter sometimes owned by importers [54]. The type
of businesses acting as terminal, intermediate and pri-
mary suppliers is described below, although as will
become clear, there is considerable overlap between
these categories in practice.
At the terminal level, wholesalers were the most common
suppliers, serving pharmacies [25-27,33,48-50,52-54,56],
drug shops [26,28,29,31-34,48,50,53,54,57,58] and general
shops [25-28,32,33,50,53,57]. In some settings, different
types of wholesalers tended to supply different types of
retail outlets. In Tanzania and Kenya, wholesalers who sup-
plied drugs alongside other commodities served general
shops [25,28,32], whilst wholesalers specialized in handling
drugs usually served pharmacies [25,27] and drug shops
[28,32].
Retailers themselves frequently operated as terminal
suppliers for outlets located in more remote areas [13],
although with variation across countries and retailer
types. Pharmacies frequently supplied rural drug shops
[26,31,48,50] and general stores [17,26,50], sometimes in
a relatively organized manner, such as in Nigeria where
they sent sales teams [17]. Drug shops were somewhat
less common terminal suppliers, at times serving other
drug shops in Uganda and Tanzania [26,29] and general
stores in Uganda only [26].
Importers were also terminal sources when they
directly served pharmacies [26,49,50,56], which they
sometimes owned [26,49,50], and also drug shops
[26,32,50], using sales teams, such as in Tanzania [32].
Public agencies were terminal suppliers, either offi-
cially such as in Sri Lanka where the State Pharmaceuti-
cal Corporation supplied retail outlets [47] or
unofficially in other countries, where government health
workers sold public sector drugs to retail shops, such as
in Uganda and Cameroon for example [18,19,48].
Terminal suppliers’ characteristics were rarely
explored. When available, the evidence shows that in
Tanzania wholesalers infrequently had any health-
related qualifications, although drug specific wholesalers
were reported to employ more qualified staff (mainly
pharmacy and biochemistry graduates) and to have been
in operation for longer than general wholesalers [32].
Information on terminal suppliers’ locations shows
that overall, remotely located drug shops and general
stores obtained their supplies more locally than more
accessible retailers. In Zambia, 24% of outlets located in
three border districts with DR Congo or Tanzania
obtained their drugs from district suppliers and the
Table 1 Published literature search strategy: databases and key words
Databases PubMed EconLit IBSS
Key words Private sector†; Commerce†*; Private providers; Retail sector; Supply chain; Distribution chain
Anti-malarials†; Malaria†; Non-prescription drugs†;Prescription drugs†; Drugs, essential†
Price; Pricing; Markup(s); Profit margin; Price component
Developing countries†; Africa†; Asia, Western†; Asia, Southeastern†; Latin America†
Private sector; Retail sector; Wholesale;
Supply chain; Anti-malarials;
Pharmaceuticals
Price; Pricing; Markup(s); Profit margin;
Price component
† Mesh term; *The interchange of goods or commodities, especially on a large scale, between different countries or between populations within the same
country. It includes trade (the buying, selling, or exchanging of commodities, whether wholesale or retail) and business (the purchase and sale of goods to make
a profit) [http://www.ncbi.nlm.nih.gov/sites/entrez, accessed 10 March 2008]. PubMed searches were limited to government publications, journal articles and
technical reports.
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Table 2 Overview of the literature
Reference Distribution chain structure Anti-malarial
products
Source of
supply
Number of
suppliers
Suppliers’
characteristics
Volumes
sold
Mark-
ups
Burkina Faso
RBM Secretariat, 2007 [77] X X - - X
Cambodia
Institute of Medicine, 2004 [48], Shretta and Guimier, 2003 [55] X X - - X
PSI, 2008 [58], Sabot, 2009 [63] X - - X X
Rozendaal, 2001 [44] X - - - -
Cameroon
Van der Geest, 1987 ± [19] X - X - -
RBM Secretariat, 2007 [54] X X - - X
Ghana
Buabeng et al., 2008 [56] X - - - -
Kenya
Marsh et al., 2004 [57] X - - - -
Ministry of Health of the Government of the Republic of Kenya,
2004 [78]
- - - - X
Myhr, 2000 [61] - - - - X
Tavrow, 2003 [25] X X X - X
Amin and Snow, 2005 [27] X - - - -
Mozambique
Russo, 2007 ± [49] X X - - -
Nigeria
Adikwu, 1996 ± [17] X - - - -
IFC, 2008 ± [52] X X - - -
Senegal
Institute of Medicine, 2004 [48], Shretta and Guimier (2003) [55] X X - X X
Kone et al., 2007 [62] X - - - X
IFC, 2008 ± [52] X X - - -
Sri Lanka
Rajakaruna et al., 2006 [47] X - - - -
Tanzania
Battersby et al., 2003 [31] X X - - X
Goodman, 2004 [20], Chukwujekwu, 2007 [32] X X X - X
Clinton Foundation, 2008 [34] X - - X X
Government of the Republic of Tanzania and Clinton
Foundation, 2008 [29]
X X - X X
Uganda
Adome et al.,1996 [18] X - - - -
The Republic of Uganda, 2004 [59] X - - - X
MMV, 2007 [26] X X - - X
Yadav and Conesa, 2008 [51] - X - - -
IFC, 2008 ± [52] X X - - -
RBM Secretariat, 2007 [54] X X - - X
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same proportion chose to cross borders to buy from
Tanzanian or Congolese suppliers [33]. In Tanzania,
drug shops generally obtained anti-malarials from drug
specific wholesalers or pharmacies located in the capital
city, hundreds of kilometres away [28,29,32], whilst
those located more than 1,000 kilometres away from the
capital city obtained their supplies from more nearby
locations [29]. In Uganda and Kenya, general shops
usually obtained their supplies from local suppliers
[25-27]. In Kenya, the location of general shops’ supply
sources varied with outlet size, such that large shops
where more than one person worked during opening
hours obtained their supplies from general wholesalers
located inside or outside the district whilst smaller
shops where one person worked during opening hours
bought more frequently from general wholesalers
located within the district [27].
Mobile suppliers, such as sales representatives of drug
companies or general distributors, served retailers in
many settings, although their popularity and the types
of outlets they served varied. In Kenya, mobile vendors
commonly supplied both drug and general shops
[25,27,57], whilst in Tanzania mobile vendors only
served general shops, representing in some districts only
1% of supply sources [28], but in others being a more
common source of supply [31]. In Nigeria, sales repre-
sentatives of large national and international drug com-
panies supplied all types of retail outlets [17]. By
contrast, in Uganda and Tanzania, local manufacturers’
sales teams supplied the more accessible retailers with
more qualified staff [26,32]. Finally, overseas manufac-
turers directly supplied retailers in Sri Lanka only where
5% of retailers obtained drugs directly from drug com-
panies in India [47].
At intermediate level, studies provided much less
information on supply sources. In settings where inter-
mediate-level suppliers were identified [26,32,48,52],
they were wholesalers who, as in the case of those oper-
ating at terminal level, either handled drugs alongside
other commodities or specialized in drugs, hence sup-
plying distinct distribution chains. Information on the
location of intermediate suppliers was available only for
Tanzania and Uganda, where they operated in the capi-
tal city [26,32] and at regional [32] or district level [26].
In Tanzania, intermediate wholesalers were sometimes
agents of upstream suppliers at regional level [32].
Regional wholesalers also, at times, used mobile services
providing door-to-door services to their customers [32].
In other settings, there was no information available at
this level or no intermediate suppliers operating in the
chain serving the studied areas [18,25,27,58]. Finally, as
at terminal level, information on suppliers’ characteris-
tics was provided by a single study reporting that in
Tanzania general suppliers had started their business
more recently than drug specific wholesalers and rarely
employed staff with health related qualifications [32].
At the top of the chain or primary level, suppliers
were importers who were agents of overseas pharma-
ceutical companies, sometimes contracted to act as
their sole supplier for distributing their products
locally [26,32,50] or, more rarely, integrated with over-
seas companies as seen in Mozambique [49]. The lit-
erature provided little information on the nature of
this agency relationship. In the case of exclusive distri-
butorship agreements between overseas companies and
local importers, the latter frequently exchanged pro-
ducts with other importers for which one or the other
was the sole supplier [26,31,32,49,50], creating hori-
zontal transactions at the top of the chain. This situa-
tion was reported in Zambia where importers tended
to have regular customers who would generally pur-
chase the bulk of their supplies from few importers. As
importers were generally the sole entry point for a par-
ticular drug, they would often exchange products
between one another [32,50] rather than send custo-
mers to buy from the relevant importer. As a result,
no clear differentiation between wholesalers and
importers existed in many settings, as these roles were
product dependent [50,59]. As at terminal and inter-
mediate levels, suppliers’ characteristics were provided
only by the study conducted in Tanzania, where drug-
specific suppliers employed more staff with health-
related qualifications and had been in operation for
longer than general suppliers [32].
Table 2: Overview of the literature (Continued)
Zambia
Institute of Medicine, 2004 [48], Shretta and Guimier, 2003 [55] X X - - X
Yadav, 2007 ± [50] X X - X -
Clinton Foundation, 2008 [33] X - - X
Low/Middle income countries
Foster, 1991 ± [13] X - - - -
Yadav and Ongola, 2007 ± [53] X X - X -
± = studies on distribution chain for pharmaceutical drugs in general (other studies are specific to anti-malarials)
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Finally, illegal distribution channels were reported in
several countries, whereby drugs were smuggled from
one country to another [19,44,48,56]. For example,
drugs smuggled from Nigeria were commonly found on
sale in Cameroon or passing through Cameroon to
reach Gabon or the Central African Republic [19]. In
Senegal, smuggling took the form of sea or air ship-
ments diverted from their initial destination or illegal
imports of donations from European countries [48].
Whilst illegal channels were commonly reported, the lit-
erature offered very limited information on their struc-
ture and actual size [19]. In Zambia, illegal importers
were found to serve wholesalers and drug shops directly
[48].
This section shows that the distribution chain is far
more complicated than as characterized in our taxon-
omy (Figure 1). Figure 2 represents what happens in
reality, as reported in the literature.
Anti-malarial sales volumes and mark-ups
Sales volume estimates are key data for assessing the
relative importance of wholesalers within the distribu-
tion chain and understanding suppliers’ pricing deci-
sions. Data on actual volumes sold across chain levels
were found in only six references [29,34,48,53,55,60].
Anti-malarial sales volumes reported by 21 wholesalers
operating across six regions of Tanzania ranged from
2,001 and 27,000 doses per month [34]. The rest of the
literature indicated relatively concentrated wholesale
markets (compared to retail markets), especially at the
top of the chain where a few suppliers were responsible
for most of the volume sold [33,51,53]. Only one study
on the anti-malarial import market in Uganda calculated
concentration ratios (the proportion of anti-malarial
sales volumes/value accounted for by the n largest
firms) and the Hirshman-Herfindahl index (HHI) (the
sum of squared market shares of each firm in the mar-
ket). The study found that five importers accounted for
nearly 72% of anti-malarial sales with a HHI of just
under 1400, indicating moderate market concentration
(an index under 1,000 is associated with competitive
markets and above 1,800 with monopoly) [51].
More attention has been paid to measuring anti-
malarial price mark-ups, especially on first-line treat-
ments for uncomplicated malaria or the most common
alternatives at the time of the studies. Methods used
included regulatory document reviews, qualitative inter-
views with key informants including government offi-
cials, wholesalers and retailers [48,54,61], sometimes
combined with semi-structured or structured interviews
with wholesalers, retailers and/or consumers (Table 3).
For the purpose of this review, mark-up data were sum-
marized using a specific taxonomy. Primary mark-ups,
therefore, refer to the margins that primary suppliers
Manufacturers  
(Local & international) 
General stores Drug shops Pharmacies 
Wholesalers 
(Drug specific & general) 
Importers 
(Drug specific & general) 
Public sector 
Figure 2 Structure of the distribution chain. This figure shows the complexity of the in-country distribution chain for anti-malarial drugs in
low and middle-income countries, as reported in the literature.
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(entry point to the distribution chain) add on top of
their purchase prices when they serve intermediate or
terminal wholesalers. Terminal mark-ups relate to mar-
gins added by terminal wholesalers (retailers’ direct sup-
ply sources) on top of the price at which they obtained
the drug, either from primary or intermediate suppliers
(Table 3).
Overall, studies reported mark-ups within the distribu-
tion chain serving pharmacies or/and drug shops, except
one that also provided anti-malarial mark ups within the
chain supplying general stores.
Within the distribution chain, mark-ups varied across
levels, ranging from 27% to 99% at primary level, 8% at
intermediate and 2% to 67% at terminal level (Table 3).
In some settings, mark ups varied depending on the
structure of the chain [26], with somewhat higher mark-
ups at a given level observed in a distribution chain
made of fewer levels. For example, in Tanzania, when
supplying regional wholesalers, importers added between
27% and 43%, whilst when directly supplying retailers
they added between 50% and 67% [29].
In the retail market, price mark-ups on anti-malarials
have been relatively more researched. They were some-
times very high and varied greatly across outlet type and
location, and anti-malarial type and packaging. There
were four key findings. First, mark-ups ranged between
3% and 566% in pharmacies, 29% and 669% in drug
shops and 100% and 233% in general shops (Table 3).
Second, mark-ups were somewhat higher in rural outlets
compared to urban ones. In Zambia, for example, the
median ACT mark-up in Lundazi, a rural district was
54% whilst in Kabwe urban district the median was 29%
[33]. In Choma, a peri urban district, the median ACT
mark-up was, however, much higher than in rural Lun-
dazi reaching 300% [33]. Third, generics tended to have
higher percentage mark-ups, a situation that may not
have translated into higher absolute margins given that
generics are generally sold at lower prices than branded
products. Fourth, mark-ups varied across packaging
types, with a mark-up of 669% on one loose tablet of
amodiaquine compared to 270% on a blistered tablet in
Tanzania [20]. Again, assuming that loose tablet prices
are lower than packed tablet prices, this may not have
automatically translated into higher absolute margins.
In some settings, where ACT subsidy schemes have
already been implemented, mark ups were within the
range expected by the managers of the schemes. In
Senegal, private pharmacies purchased the subsidized
first-line ACT from public sector medical stores and
added on average 35% to the price of an adult dose,
which translated into a retail price only 4% higher than
the recommended retail price (RRP) [60,62]. In two dis-
tricts of Tanzania, a subsidy scheme was piloted in drug
shops and in one of these two districts, it was combined
with a RRP printed on ACT packs. ACT availability
increased and the subsidy effectively decreased the price
of ACT below the price paid by consumers in the con-
trol area and below the price of older anti-malarials,
leading to a large increase in the proportion of anti-
malarial consumers purchasing ACT in the two inter-
vention areas (from 1% to 44.2% one year later) [63].
Surprisingly, ACT prices were higher in the district with
the RRP than in the district without, suggesting caution
in future use of this approach for controlling ACT retail
prices [63]. In Cambodia, a contrasting experience of a
subsidy scheme was reported. Cambodia is the first
country to have switched its first-line treatment to ACT
and implemented a social marketing programme, includ-
ing a subsidy, packs printed with RRP and mass com-
munication campaigns in its endemic provinces. Market
penetration of the subsidized ACT remained relatively
low and ACT retailed, on average, at a price 70% higher
than the RRP [60].
Overall, relatively little is known about the factors that
influence pricing decisions. Only one study was identi-
fied which used multivariate statistical methods to ana-
lyse price determinants, examining prices in drug and
general retail shops selling anti-malarials in rural Tanza-
nia. The study found that higher retail prices were asso-
ciated with branded and packed products, being sold in
general shops (which might have reflected higher prices
charged by their terminal supply sources) and higher
market concentration [16,20]. The rest of the literature
provided descriptive findings. Retail and wholesale mar-
gins were reported to be influenced by fixed price or
margin regulation or, in the absence of regulation, mar-
ket competition and consumer demand. Wholesale pri-
cing decisions were also reported to be influenced by
product characteristics, business practices and costs
[26,32,54]. In Uganda, markups were reported to be
lower for anti-malarials with shorter shelf life [26]. In
Tanzania, drug wholesalers reported giving discounts to
customers who bought drugs in relatively large quanti-
ties [32], and general wholesalers to customers who pur-
chased drugs alongside other commodities [32]. One
wholesaler also reported adding 6-7% to cover his
expenses and 3-4% for profit [32].
Discussion
The existing evidence on the retail sector distribution
chain for anti-malarial drugs was reviewed by identifying
32 references across 12 low and middle-income coun-
tries. The distribution chain has a pyramid shape and its
structure varies greatly across countries and within
countries across outlet types, with chains having more
levels when serving rural and less formal outlets. There
was also some indication of weak competition especially
at primary level, where few wholesalers accounted for
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Table 3 Mark ups on anti-malarial drugs
Country Methods (study
reference)
Generic
name*
(drug type
or brand)
Product
description,
(as provided
in the
literature)
Mark ups across supply chain levels
Primary Intermediate
1
Intermediate
2
Terminal Retail (location where
available)
Pharmacies Drug
shops
General
shops
Burkina Document CQ 1 dose - - - - 100% - -
Faso review; SP 1 dose - - - - 100% - -
KII§ Semi-
structured
interviews with
suppliers [54]
ACT 1 dose - - - 30% 100% - -
Cameroon KII [54] ACT 1 dose - - - 14% 34% - -
Cambodia Semi- AS 18 tablets - - - 2% 3% - -
structured
interviews with
suppliers and
retailers [48,55]
AS+M ±
(Malarine®)
Child dose - - - 50% 3% - -
Structured
interviews with
suppliers [58]
AS+M ±
(Malarine®)
Adult dose - - - - 71% ** -
AS+M ±
(Malarine®)
Child dose - - - - 65% ** -
AS+M2 8 tablets - - - - 29% ** -
AS+M3 12 tablets - - - - 15% ** -
AS+M4 17 tablets - - - - 16% ** -
Kenya KII and
structured survey
of retailers [78]
AQ (IB) 9 tablets 40% - - 15% 33% - -
SP (IB) 3 tablets 29.5% - - 15% 33% - -
SP (G, LPG) 3 tablets - - - 15% 203% - -
Semi-structured
interviews with
retailers [25]
AQ
(Malaramed®)
Child dose,
syrup
- - - - 86% - -
AQ
(Amobin®)
Child dose,
syrup
- - - - 22.9% - -
AQ
(Malaratab®)
Child dose - - - - 189% - -
SP
(Laridox®)
Child dose - - - - 151% - -
SP
(Fansidar®)
Child dose - - - - 13% - -
SP
(Falcidin®)
Child dose - - - - 28% - -
Document
review [61]
AMs - - - - 15% 20% - -
KII [54] ACT 1 pack - - - 10% 33% - -
Senegal KII; Mystery
shopper
technique at
retail level [62]
AS+AQ ± Adult dose - - - 15% 3-5% - -
Child dose - - - 15% 11-22% - -
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Table 3: Mark ups on anti-malarial drugs (Continued)
Semi-structured
interviews with
suppliers and
retailers [55]
Q (IB, BG) 1 dose
(injection)
- - - 18% 41% -
Q (G) 1 dose
(injection)
- - - 15% 30% -
Tanzania Semi-structured
interviews with
suppliers and
retailers [20,32]
AQ 1 tablet - - - 9% - 270%-
669%
(rural)
-
AQ 1 tablet - - 8% - - - -
Q 1 tablet - - - 26% - 150%-
203%
(rural)
-
Semi-structured
interviews with
suppliers and
retailers [31]
SP 3 tablets 48% - - 13% - - 100-
233%
Semi-structured
interviews with
suppliers and
retailers [29,30]
AL (IB) ±i 5<15 kg dose - - - 67% ** - 100-
200%
-
15<25 kg dose - - - 56% ** - 60%-
221%
-
25<35 kg dose - - - 52% ** - 47%-
230%
-
35+ kg dose - - - 50% ** - 39%-
233%
-
AL (IB) ±ii 5 <15 kg dose 43% - - - - 100-
200%
-
15<25 kg dose 34% - - - - 60%-
221%
-
25<35 kg dose 31% - - - - 47%-
230%
-
35+ kg dose 27-30%
**
- - - - 39%-
233%
-
Semi-structured
interviews with
suppliers and
retailers [34]
ACT (IB) n/a† - - - 21% - 54%
(rural)
-
AMT(IB) n/a† - - - 18% - 44%
(rural)
-
SP n/a† - - - 23% - 110%
(rural)
-
AQ n/a† - - - 41% - 96%
(rural)
-
Quinine n/a† - - - 38% - 64%
(rural)
-
Uganda Semi-structured
interviews with
suppliers and
retailers [59]
SP (MSG) 3 tablets - - 6% - 410% - -
SP (LPG) 3 tablets 27% - - 29% 501% - -
KII; Semi-
structured
interviews with
retailers [54]
All AMs n/a 40-50% - - 7-8% - - -
AL (G) 1 dose - - - - 38% -
CQ (G) 1 dose - - - - 100% -
Patouillard et al. Malaria Journal 2010, 9:50
http://www.malariajournal.com/content/9/1/50
Page 10 of 14
Table 3: Mark ups on anti-malarial drugs (Continued)
Semi-structured
interviews with
suppliers and
retailers [26]
DHA+PP (IB) 1 tablet 32% - - 14% - 29%
(rural)
-
DHA+PP (IB) 1 tablet 32% - - 21% 22% (rural) - -
SP (IB) 1 tablet 57% - - 8% - 43%
(rural)
-
SP (IB) 1 tablet 57% - - 16% 50%(rural) - -
SP (G) 1 tablet - - - 40% - 198%
(rural)
-
SP (G) 1 tablet - - - 13% 271%(rural) - -
CQ (G) 1 tablet - - - 18% 152%(rural) - -
Artemether
(IB)
1 ampoule 99% - - 33% - 50%
(rural)
-
Artemether
(IB)
1 ampoule 56% - - 16% 28%(rural) - -
SP (G) 1 tablet - - - 25% - 200%
(rural)
-
CQ (G) 1 tablet - - - 41% - 92%
(rural)
-
DHA+PP (IB) 1 tablet 36% - - 11% 65%(urban) - -
Artemether 1 ampoule 56% - - 17% - 136%
(urban)
-
Artemether 1 ampoule 56% - - 17% 82%(urban) - -
SP (IB) 1 tablet 57% - - 5% 85%(urban) - -
SP (G) 1 tablet - - - 25% 566%
(urban)
- -
CQ (G) 1 tablet - - - 24% 143%
(urban)
- -
Zambia Structured
interviews with
suppliers [33]
ACT - - - - - - 60% -
SP - - - - - 182% - -
ACT - - - - - 29%, 11%-100% (urban)
ACT - - - - - 67%,13%-100% (peri-urban)
ACT - - - - - 54%, 50-100% (rural)
SP - - - - - 50%, 15%-327% (urban)
SP - - - - - 300%, 50%-517% (peri-urban)
SP - - - - - 50%, 15%-500% (rural)
Semi-structured
interviews with
suppliers and
retailers [48,55]
Selected AM
¥
- - - - - 30%
* AM = anti-malarials; AMT = artemisinin monotherapies; mg = milligrams; ml = millilitres; AS = Artesunate; M = Mefloquine; AS+M2 = combination for children
weighing between 16 kgs to 24 kgs; AS+M3 = combination for children weighing between 25 kgs to 35 kgs; AS+M4 = combination for adults; AQ =
Amodiaquine; SP = Sulphadoxine-Pyrimethamine; Q = Quinine; AL = Artemether-Lumefantrine; DHA+PP = Dihydroartemisinin+Piperaquine; IB = imported
innovator brand, IG = imported generic, B = branded; G = locally produced generic, MSG = most sold generic, LPG = lowest priced generic, BG = branded
generic; I = imported, LP = locally produced; SC = supply chain; ± = subsidized product; - = level of the chain did not exist or data not available; **Author’s own
calculations; † mean across all products within drug class. i primary supplier is the terminal supplier, ii primary supplier sells to terminal regional supplier. ¥
included AQ (3 tablets), Artemether (not stated), AS (6 tablets), CQ (1000 tablets), DHA (not stated), Halofantrine (6 tablets), Mefloquine (3 tablets), Proguanil (not
stated), Q (1000 tablets), AL IB (6 tablets), SP (3 tablets). IFC = International Finance Corporation. Mark-up data were rounded to the nearest whole number. §KII =
key informant interviews; Mystery shopper technique = unobtrusive observation of shop attendants by researchers who pose as client seeking care from a
provider who is unaware of their identity.
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most of the anti-malarial volumes sold. Wholesale mark-
ups were lower than retail mark-ups and these varied
across chain levels and anti-malarial drug types.
Overall, there was a lack of representative data on a
national scale, which made the interpretation of data
difficult. Studies tended to focus on the distribution
chain serving a single type of outlet, often the more for-
mal type, such as pharmacies generally operating in
urbanized settings. Data on the number of wholesalers
who operate across levels was restricted to registered
businesses and information on their characteristics was
generally lacking. Studies were mainly descriptive and
provided limited evidence on the influence of the distri-
bution chain on retail anti-malarial availability and
prices. Sales volume data across chain levels were non-
existent and mark-up data were concentrated at retail
and terminal levels, with less information at primary
and particularly intermediate levels (one study only).
This situation can be explained by the methods that
have been used to study key variables, which were often
limited to document reviews and interviews with key
informants (central government, industry representa-
tives) or retailers. Evidence on stocking and pricing
decisions within the distribution chain was therefore
lacking, an important knowledge gap for improving con-
sumers’ access to affordable quality malaria treatment.
High mark-ups and prices are commonly perceived as a
sign of high profit, often leading to calls for medicine
price reduction [64]. However, without information that
disaggregates mark-ups into profits and costs it is
unclear if such measures are appropriate.
A strong interest in working with retailers to improve
the quality of care they provide has emerged in recent
years. Goodman and colleagues identified 16 interven-
tions working with medicine sellers to improve malaria
treatment, all including a mix of activities such as train-
ing and capacity building, demand generation, quality
assurance and creation of an enabling environment [28].
However, only two of the 16 interventions were imple-
mented within the distribution chain, involving training
wholesalers and mobile vendors in Kenya and sales
representatives in Madagascar. Whilst the evidence
available on the outcomes of these initiatives was weak
and particularly limited in terms of the sustainability
and equity of benefits, it showed some improvements in
retailers’ knowledge and/or performance [28].
The Affordable Medicine Facility for malaria (AMFm)
[65] aims to increase coverage of effective treatment and
delay the development of drug resistance, by subsidizing
ACT at the top of the distribution chain and imple-
menting supporting interventions such as training, regu-
latory strengthening and consumer education. The
capacity of AMFm to meet its goals has been extensively
debated [66-68], including how the structure of the dis-
tribution chain and nature of competition at all levels
will affect final prices. Sceptics are concerned that the
subsidy will be captured by middle-men within the pri-
vate commercial supply chain and informal unqualified
profit-maximizing retailers. This review indicates that
there is insufficient evidence on anti-malarial distribu-
tion chains to predict with confidence what the outcome
will be, particularly reflecting inadequate information on
profit margins and the factors that influence pricing
decisions. On the one hand, relatively concentrated mar-
kets (few suppliers accounting for large share of sales)
were documented at the primary supplier level in
Uganda and Zambia, accompanied by frequent exclusive
dealership relationships, and within local areas at retail
level, indicating the potential for exploitation of market
power. On the other hand, early experiences of subsidiz-
ing ACT provide valuable lessons, notably the impor-
tance of rigorous distribution chain analysis, for
example to set the RRP at an appropriate level. Redu-
cing the price of ACT will however not suffice and
accompanying interventions need to be identified and
tailored to each country context [69]. For example,
Rapid Diagnostic Tests (RDTs) have the potential to
increase access to accurate diagnosis and appropriate
treatment, especially in remote areas where alternative
routine microscopy services cannot easily be made avail-
able [70-73]. However, the distribution of affordable
quality RDTs is also not without challenges [71,74,75]
and has been the object of little research to date [76].
Conclusions
Available evidence on the distribution chain for retail
sector malaria treatment provides some useful descrip-
tive information, but there is a lack of nationally repre-
sentative data, and of analysis of the determinants of
supplier behaviour. In the advent of the AMFm, a better
understanding of the role of the anti-malarial distribu-
tion chain on retail outcomes is urgently needed. Retai-
lers are likely to remain an important source of malaria
treatment and the knowledge gaps identified here could
jeopardize the success of initiatives for improving ACT
access. Addressing these uncertainties should be a prior-
ity of ongoing and future research.
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